title: Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario.
abstract: Brain metastases from prostate cancer (PC) seem to be more frequent than in the past, possibly because advances in the treatment of patients with castration-resistant PC have prolonged their survival. Furthermore, docetaxel (the drug of choice for the first-line treatment of castration-resistant PC) cannot cross the blood-brain barrier and control metastatic foci. However, this problem may be overcome by new active drugs such as cabazitaxel.
authors.affiliation: Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38100 Trento, Italy. orazio.caffo@apss.tn.it
authors.forename: Orazio
authors.initials: O
authors.lastname: Caffo
authors.forename: Antonello
authors.initials: A
authors.lastname: Veccia
authors.forename: Lucianna
authors.initials: L
authors.lastname: Russo
authors.forename: Enzo
authors.initials: E
authors.lastname: Galligioni
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001932:Brain Neoplasms / Q000453:epidemiology* / Q000556:secondary* / Q000601:surgery; D000077143:Docetaxel; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology*; D043823:Taxoids / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; C552428:cabazitaxel